136 related articles for article (PubMed ID: 19345354)
1. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.
de Vries-van der Weij J; Zadelaar S; Toet K; Havekes LM; Kooistra T; Rensen PC
Atherosclerosis; 2009 Sep; 206(1):153-8. PubMed ID: 19345354
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
4. CETP expression reverses the reconstituted HDL-induced increase in VLDL.
Wang Y; Berbée JF; Stroes ES; Smit JW; Havekes LM; Romijn JA; Rensen PC
J Lipid Res; 2011 Aug; 52(8):1533-41. PubMed ID: 21606464
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
[TBL] [Abstract][Full Text] [Related]
6. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.
Bijland S; van den Berg SA; Voshol PJ; van den Hoek AM; Princen HM; Havekes LM; Rensen PC; Willems van Dijk K
J Lipid Res; 2010 Jan; 51(1):97-102. PubMed ID: 19564641
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
9. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
[TBL] [Abstract][Full Text] [Related]
10. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia.
Fazio S; Marotti KR; Lee YL; Castle CK; Melchior GW; Rall SC
J Biol Chem; 1994 Dec; 269(51):32368-72. PubMed ID: 7798236
[TBL] [Abstract][Full Text] [Related]
12. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
[TBL] [Abstract][Full Text] [Related]
13. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
14. PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.
de Haan W; de Vries-van der Weij J; Mol IM; Hoekstra M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Biochim Biophys Acta; 2009 Mar; 1791(3):191-7. PubMed ID: 19150509
[TBL] [Abstract][Full Text] [Related]
15. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
Harder C; Lau P; Meng A; Whitman SC; McPherson R
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):858-64. PubMed ID: 17272756
[TBL] [Abstract][Full Text] [Related]
17. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
Marotti KR; Castle CK; Boyle TP; Lin AH; Murray RW; Melchior GW
Nature; 1993 Jul; 364(6432):73-5. PubMed ID: 8316302
[TBL] [Abstract][Full Text] [Related]
18. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.
Van Eck M; Ye D; Hildebrand RB; Kar Kruijt J; de Haan W; Hoekstra M; Rensen PC; Ehnholm C; Jauhiainen M; Van Berkel TJ
Circ Res; 2007 Mar; 100(5):678-85. PubMed ID: 17293475
[TBL] [Abstract][Full Text] [Related]
19. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
20. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
